News and Press Releases

logo

BrightStar Wisconsin invests in SHINE

BrightStar Wisconsin Foundation Inc. today announced that it has invested a total of $1 million in five additional companies, Dairyvative Technologies  LLC, Shine Medical Technologies Inc., Fetch Rewards Inc., Medical Companion LLC (doing business as mPirik), and Keystone Insights Inc.

pi_180-pnl

SHINE Medical Technologies and Phoenix Nuclear Labs Sign Multi-year Development and Supply Agreement

January 7, 2015 – SHINE Medical Technologies and Phoenix Nuclear Labs (PNL) announced today that they have entered into an exclusive, long-term development and supply agreement. This agreement builds on an existing partnership and lays the foundation for a commercial relationship going forward.

SHINE Stays Ahead of The Competition: Founder

There’s no shortage of companies that want to fill an impending gap in North American medical isotope production.

A Google search offers plenty of evidence, said Greg Piefer, founder and chairman of SHINE Medical Technologies, the company that starting in 2018 plans to make molybdenum-99 and other medical isotopes in Janesville.

tututyuty

SHINE Offers New Technology to Alleviate Mo-99 Shortage

Since the severe global molybdenum-99 (Mo-99) shortage of 2009 and 2010, nuclear medicine practitioners have been glancing back over their collective shoulders to see when the next crisis might occur. Fortunately, plans are in the works to eliminate the angst of another medical isotope shortage, with one such effort coming from SHINE Medical Technologies.

Header_02

Lantheus Medical Imaging and SHINE Medical Announce Mo-99 Supply Agreement

November 5, 2014 – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, and SHINE Medical Technologies, Inc., a Wisconsin-based company dedicated to being the world leader in safe, clean, affordable production of medical isotopes, today announced that the companies have entered into a strategic agreement for the future supply of molybdenum-99 (Mo-99).

Shine Medical Technologies Logo

SHINE Medical Signs $125 Million Term Sheet

SHINE Medical Technologies, Inc. (SHINE) announced today that it executed a term sheet providing for up to $125 million of debt and equity financing with Deerfield Management Company, L.P. (Deerfield), a New York headquartered healthcare investment firm. SHINE plans to build a new manufacturing plant in Wisconsin to produce more than a quarter of world supply of the most commonly-used isotope in nuclear medicine, molybdenum-99 (moly-99).

Shine Medical Technologies Logo

SHINE Medical Secures $2.4 Million of Investment

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that it closed a $2.4 million financing.

pi_180-pnl

SHINE Medical and Phoenix Nuclear Achieve Key Technical Milestone

SHINE Medical Technologies and Phoenix Nuclear Labs (PNL) announced today that they successfully operated their second-generation neutron driver prototype for 24 consecutive hours with 99% uptime. Completion of this milestone is an important demonstration of the reliability and robustness of the PNL neutron driver, which is a key enabling technology for SHINE’s isotope production facility.